If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave breaks down the news of the week and puts it all in context.

Topics:

The GLP-1 paradox, Rise of telehealth powerhouses, FDA guidance on compounding, Enforcement risks and industry impact, Peptide imports and gray market concerns, New branded drug developments, Expansion of oral GLP-1 medications, New oral drug launches, Where the market is heading.